In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Invivyd (IVVD – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.12.
According to TipRanks, Trucchio is an analyst with an average return of -19.1% and a 27.85% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Alnylam Pharma, and Oncolytics Biotech.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Invivyd with a $5.00 average price target.
See today’s best-performing stocks on TipRanks >>
Based on Invivyd’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.32 million. In comparison, last year the company had a GAAP net loss of $100.67 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
Read More on IVVD:
- Invivyd announces alignment with FDA on pathway to potential VYD222 EUA
- Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
- Invivyd announces initial data from ongoing Phase 1 trial of VYD222
- Invivyd to Participate at the Jefferies Healthcare Conference
- Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
